Updates on EPC, PCT, EPO case law and the e-EQE

EP 3 248 477 B1 relates to an insertion device and to a rod making machine for the tobacco processing industry.

The insertion device=a trough, minimises the risk that, if a rod-shaped article, such as a filter segment, is missing in a trough of the insertion device, the suction air collapses in such a way that other rod-shaped articles arranged or picked up in the trough can no longer be held or can no longer be held precisely,

EP 3 167 888 B1 relates to the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by an inhibitor of complement. The product is known as eculizumab.

It stems from a third generation divisional of EP 2 359 834 A1 and EP 2 001 490 A1 filed as PCT/US2007/006606 and published under WO 2007/106585

Brief outline of the procedure before the EPO

Proprietor is Alexion Pharmaceuticals,

EP 3 483 299 A1 relates to a steel material for hot stamp forming with ultra-fine grains and a process of making the same, a hot stamp forming process and a hot stamp formed member. It has been published in accordance with Art. 153(4) and goes back to the application PCT/CN2016/098411 published as WO 2018/006490.

Brief outline of the case

The unsuccessful candidate to the EQE appealed the decision of the EQE Examination Board that he had not passed the EQE.

With decision D33/22, the Disciplinary Board of Appeal (DBA) rejected the appeal.

The candidate filed a petition for review against the decision of the DBA.

EP 3 725 778 B1 relates to solid formulations of enzalutamide. More particularly, this disclosure relates to pharmaceutical compositions comprising a solid dispersion containing enzalutamide and at least one polymer.

EP 3 725 778 B1 is a divisional  application of EP 2 895 463 A1, originally published under WO 2014/043208.